EY has announced the acquisition of Aqurance, a Veeva services partner headquartered in Greece, known for delivering integrated clinical, commercial and digital transformation programs for life sciences companies worldwide. 

This strategic acquisition enhances the EY organization’s life sciences capabilities by combining EY’s extensive experience in regulatory compliance, business design, change management, technology integration, and operations with Aqurance’s deep expertise in Veeva Vault and Veeva applications. As a new Veeva alliance partner, EY aims to help clients optimize and integrate Veeva solutions to drive greater efficiency, compliance, and innovation across the life sciences ecosystem. 

Aqurance holds the designation of Premier Services Partner for Veeva Commercial Cloud and Services Partner for Veeva Development Cloud, bringing significant consulting expertise across both commercial and R&D domains. The acquisition strengthens EY’s Veeva Centers of Excellence, enhancing its ability to support pharmaceutical and biotech clients through Vault CRM migrations, regulatory transformation, and enterprise-wide platform integration. 

By combining capabilities, EY and Aqurance will help life sciences organizations harness the power of artificial intelligence (AI) and enterprise data to accelerate clinical trials, improve customer engagement, and achieve consistent regulatory compliance across global operations. 

Dan Mathews, EY Global Life Sciences Leader, commented: “This is a pivotal moment for the industry as life sciences companies make critical decisions about platform migration, compliance, and data integration. With the acquisition of Aqurance, EY can offer clients a seamless, end-to-end pathway—from strategy to execution—to unlock the full potential of Veeva technology. Together, we’ll help companies move faster, stay compliant, and use data and AI to make smarter, more informed decisions.” 

Dionissis Nikolopoulos, Founder & CEO of Aqurance, added: “When planning our next chapter, EY stood out as the ideal partner. EY’s scale, global reach, and deep industry credibility allow our expertise to make a far greater impact. By combining Aqurance’s Veeva specialization with EY’s transformation capabilities, we can deliver unmatched value—from seamless migrations to enterprise-wide digital change that moves the needle for the life sciences industry.” 

With this acquisition, EY is uniquely positioned to provide integrated migration and transformation capabilities that help life sciences companies adapt to evolving market dynamics, regulatory requirements, and the growing demand for connected digital platforms.